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Clinician researchers have a number of roles, each of which carries specific obligations.
There are times when these obligations may be in competition (up to and including
conflict) with each other. Using a narrative case study that describes a group of col-
leagues discussing their clinical department’s participation in an industry-sponsored
research protocol, we illustrate a number of the obligations faced by clinician research-
ers, and discuss how competing interests and obligations can lead to ethical problems.
The case study is followed by a discussion of the effect of university–industry relations
on competing interests and obligations in both clinical research and the role of the
university, and a suggested framework that could be used to determine when university
involvement in commercial research is ethically acceptable.
Keywords: clinical research ethics, competing interests, conflicts of interest, research
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DR. CÉZANNE’S STORY
Dr. Cézanne and his colleagues sit in silence as they prepare to discuss their
participation in the pharmaceutical company–sponsored clinical trial
described in the pile of documents lying on the table in front of them. Only
Address correspondence to Jeff Nisker, London Health Sciences Centre, Victoria
Hospital, Room E5-324, 800 Commissioners Rd., E., London, Ontario, Canada.
E-mail: jeff.nisker@lhsc.on.ca
86 R. L. Bluhm et al.
their signatures are required for this multicenter and multimillion-dollar,
predesigned, and prepackaged proposal to proceed to their university’s
research ethics board (REB). Dr. Cézanne knows he will be alone in his oppo-
sition to the proposal. His colleagues know they will patiently listen to
Dr. Cézanne’s concerns, which he has brought to this table many times, and
which they will disregard again, even though they respect Dr. Cézanne as a
serious scientist and as a caring physician. It is indeed because they respect
their well-intentioned but impractical friend, and because they all see them-
selves as “honorable men” that they patiently commence the discussion that
they already know will lead to the decision to participate in the trial. It’s like a
game where the result has been predetermined.
One of Dr. Cézanne’s colleagues plays his standard opening scientifically-
sound card. “This study is a well-designed, placebo-controlled, double-blind,
randomized trial investigating the efficacy and safety of a hormone replace-
ment therapy. On page 7 of the drug company’s proposal, you can see that the
number of patients that will be recruited nationally has the statistical power
to answer the scientific questions regarding whether the drug is effective and
safe. The methods of data analysis described on page 28 are appropriate. The
proposal is scientifically sound, and we should participate.”
Dr. Cézanne knows well the cards not-so-well concealed in his colleagues’
well-intentioned, science-driven, budget-responsible hands; powerful cards
that compel the embrace of pharmaceutical company--sponsored research. He
counters with his re(peat)search card. “The proposed research is not
research at all. It is re(peat)search of a drug that has been approved and pre-
scribed for 10 years in Europe and 7 years in the United States. The only
justification for repeating the study on women in Canada would be if we
believe physiological differences exist between women in Canada and women
in the United States or Europe that might affect their tolerance of the drug or
their risk of neoplasia. If physiological differences do exist, they are more
likely based on ethnic origin than on country of residence. Although environ-
ment and diet are potential variables, these are more likely to vary within
each country than between sides of the 49th parallel of the Atlantic Ocean.
A colleague promptly plays his Health-Canada-insists card. “You are
correct, Dr. Cézanne, the study is re(peat)search, but it is required by the
Therapeutic Products Directorate of Health Canada before patients can be
prescribed this drug in Canada. The pharmaceutical companies are forced by
Health Canada to spend their millions.”
Dr. Cézanne quickly counters his lack-of-clinical-equipoise-card. “If
the pharmaceutical companies must spend millions, why not spend the
millions on a proper clinical trial? This study is not research, for it lacks clinical
equipoise (Freedman, 1987). The Canadian philosopher, Benjamin Freedman,
coined the term ‘clinical equipoise’ to remind us that if the results of the study
are apparent before the study commences, the study is not research. We
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should change the protocol to compare the drug to the current gold standard
instead of placebo (Weijer, 1999; Weijer et al., 2000) and if the new product is
more effective, and at least equally safe, we will learn something from the
study rather than possibly causing harm to Canadian women and gaining no
new knowledge. The pain from the endometrial biopsies required by the proto-
col and, for the women who receive placebo, the discomfort of their symptoms,
would be an unjustifiable harm.”
A colleague utters, “You know we can’t change the protocol” as he plays
his participation-is-in-the-best-interests-of-the-women-who-participate
card. “A woman, by enrolling in research, can receive a drug that might better
alleviate or even cure her problem years before it will be available to her by
prescription. There is also evidence that patients who participate in clinical
research may have better outcomes than those who do not (Braunholz et al.,
2001). And don’t forget, the women in the study will get the drugs for free and
that is a significant benefit.”
Dr. Cézanne plays his non-nocere card. “This proposal requires that all
women undergo endometrial biopsy to rule out endometrial neoplasia before
they can be entered in the study---all women---and these women cannot have
a medical indication for endometrial biopsy or they would not have met entry
criteria. Venepuncture, although less painful, is also required. Patients should
not be asked by their physicians to endure painful procedures with no benefit
to science. We take an oath not to harm our patients (Hippocrates, 1943) and
this unnecessary pain is harmful.”
A colleague counters with his patient-choice card, “Our patients will not
be forced to participate in this study. They will be offered the opportunity to
freely choose to participate, and, if they decide to participate, they will sign a
consent form indicating that they freely chose to participate. Our patients will
be educated about the risks and potential benefits by the study nurse before
they consent. After considering what the study nurse has said, a patient can
simply say, ‘I’d rather not.’”
Dr. Cézanne counters with his lack-of-true-choice card: “Rare is the
patient who has the courage to refuse her physician’s offer to enroll her in
a clinical trial, as she perceives her refusal as threatening to her prospects
for good care in the future (Baylis, 1989; Kenny, 1994; Sherwin, 1994;
Nisker and White, 2005). The woman fears her physician will think less of
her if she refuses to participate in a study that might forward the science
that will help other women, and she is sure the study her doctor is offering
is important or her doctor would not be asking. If she refuses, she feels she
will offend her doctor. Further, many patients feel the study drug is
another treatment option (Kass et al., 1996), the option their doctors want
them to take.”
A colleague smiles and plays his more-choice-for-women-card. “Clinical
trials, such as the one before us, are necessary to afford Canadian women the
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maximum number of choices for the best drugs available. I cannot believe you
of all people, Dr. Cézanne, would want to limit women’s choices.”
Dr. Cézanne plays his more-marketing-than-measuring card. “But the
proposed study, designed this way, is really just a marketing tool. The motiva-
tion for the pharmaceutical company is to introduce their product to academic
physicians like us, who will later introduce their product to private practice
physicians at ‘drug dinners,’ ‘drug lunches,’ and ‘getaway’ conferences. We
unknowingly advertise their product in every letter we write to referring
physicians regarding their patient qua research subject.”
A colleague plays his let-our-research-ethics-board-decide card. “Our
university’s REB is well-known for screening research. You know how
seriously its members take their jobs. Why do you think you know more than
the members of our REB?”
Dr. Cézanne counters with his lack-of-REB-knowledge-of-nuance
card (Palca, 1996; Annas, 1994)” “The capacity for appropriate REB review
rests firmly on the shoulders of the researchers whose signatures declare not
only what is required on the REB application form (carefully completed by
pharmaceutical company or contract research staff), but all information rele-
vant to the REB deliberations. It is only fair to the REB members (and espe-
cially to the women who will endure the pain) that it is clear that the
proposal is re(peat)search and that the gold standard drug is not part of the
study, without camouflaging these facts in creative wording, or submerging
them in euphemisms extolling the importance of the research to Canadian
women. REB members rely on us researchers to fully inform them of the spe-
cific ingredients and scientific worth of the study (Bok, 1995), and their
study approval is inexorably linked to their confidence in our understanding
and integrity. We must, therefore, appreciate that our signatures today will
be interpreted by our REB as support of all aspects of the proposal; to con-
done, not just non-condemn.”
A colleague plays his imperative-to-do-research card. “If our center par-
ticipates in this study, large amounts of the administrative money that will be
accrued by the Department will fund new research projects of yours, and
many clinicians and trainees will have the opportunity to develop clinical
research skills, write papers, and ultimately apply for funding to be indepen-
dent investigators. Research is an imperative of our center, and studies like
this one are an important source of research funding.”
Dr. Cézanne plays his obligation-to-financial-transparency card:
“Our center receives hundreds of thousands of dollars for this ‘imperative,’
and we researchers personally receive a thousand dollar ‘finder’s fee’ for
each patient who becomes a participant. Our patients have the right to know
that we benefit financially. But by telling a patient we will receive a thou-
sand dollars if they consent to participate in the research, we may further
confine her choice in favor of ‘volunteering,’ as she may believe that she will
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hurt her physician’s opinion of her if she refuses, and also hurt her physi-
cian’s bank account and the bank account of the institution that is providing
her care.”
One of Dr. Cézanne’s colleagues exclaims: “Why do you always focus on
the negative features of every clinical trial that lands on this table?” while he
proudly plays his no-restriction-to-publication card. “There are so many
positive features of this study. For example, nowhere in the 35 pages in front
of you will you find any encumbrance on our ability to publish the results of
this study, no matter if the results declare the drug we are testing to be clini-
cally useless or even harmful.”
Dr. Cézanne nods that no clause inhibits publication of the findings, which is
irrelevant for this type of study. There will be no possibility for publication
because there will be no new findings. Though his colleagues have seen the recent
media stories and medical journal warnings (Gibson et al., 2002; Davidoff et al.,
2001) in this regard, Dr. Cézanne is concerned that his colleagues do not go deep
enough, so he counters with his International-Council-of-Medical-Journal-
Editors (ICMJE) card.
“Although the pharmaceutical company may not be prohibiting publica-
tion of the results, the ICMJE will not allow its publication, as we will be
breaking their rules. The pharmaceutical company designed the study, will
analyze and interpret the data, and have a large part in writing the results-–
and this means that many reputable journals will refuse to publish it. We owe
it to our students, our patients, our research participants, and indeed our-
selves to participate only in studies of adequate merit to be publishable in
ICMJE journals.”
Dr. Cézanne sees the shoulders slump around the table, like heavy rocks
around a smoldering campfire. No “Kumbaya” warms this communal contempla-
tion. Rather all are chilled by the silence. Finally, trying to move the card game to
its inevitable conclusion, the Department Chair plays his why-can’t-you-
compromise card. He notes that, “Many other physicians, in many other
Canadian centers have already agreed to participate in this study. Seven
university REBs have already approved this study. Are you suggesting they
are not moral physicians? Are the members of those REBs not moral? Are we,
in our Department, by choosing a road other than your high road, not moral
men? I can’t believe you believe that. Can’t you compromise a little?”
Dr. Cézanne plays his final card, his ethics-is-not-compromisable card.
He knows his Department’s Chair colleague means “compromise” as a
“balancing equation” or “arbitration process to synthesize individual view-
points to a group viewpoint.” But Dr. Cézanne hears “compromise” as “adjust
by concessions,” “expose to risk, suspicion, or disrepute,” “imperil.”
Dr. Cézanne hears “compromise” with increasing frequency, increasingly
branding his concerns as strident idealism inconsistent with modern research
realism. Dr. Cézanne is concerned his views separate him from his colleagues.
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Philosophers have often been isolated for their positions: Socrates with hem-
lock, Spinoza with excommunication, Voltaire with spending his life on the bor-
der of France and Switzerland near rapid retreat from whichever government
he had most recently enraged. But Dr. Cézanne is not a philosopher. He is a
caring physician, and he doesn’t want to be cut off from their colleagues for
caring.
Post-Cards
Dr. Cézanne still sits at that table. So do his colleagues and other physi-
cians in his and other institutions. Dr. Cézanne feels sorry for colleagues
who cannot feel the fears that drive his argument. He understands “we can
be ethical only in relation to something we can feel, understand, love, or oth-
erwise have faith in” (Leopold, 1962). He feels sorry that through their train-
ing in “miles of medical ink” and “consuming call schedules,” his colleagues
no longer maintain the idealism of their youth (Nisker, 1997, 2003), or the
calling to caring (Kenny, 2002) that carried them to medical school. But if
his colleagues’ views have become out-of-focus through wearing the multiple
professional lenses of clinician and researcher, should he not keep trying to
re-refract their view?
Ethical decisions must be looked at within the context of their society, and
particularly relationships between individuals and institutions within their
society. As governments reduce research sponsorship, as hospitals face insol-
vency, and as universities fear for their future, will fiscal pressure force
fracture between fiscally-based and ethically-based medical research?
Dr. Cézanne believes that the REB process is but a fabric, the tightness of
weave largely dependent on the pens of the researchers. Dr. Cézanne hopes
national and international explorations will help sensitize researchers sub-
mitting proposals to their REBs, to not only play by national and interna-
tional rules, but to play within their spirit.
DISCUSSION
In the analysis of the story, we draw on the literatures on conflicts of interest,
clinical equipoise, and the commercialization of research in public institutions
to explore the issues raised by Cr. Cézanne’s story.
Although one might argue that enlisting patients to participate in the
study could be considered a conflict of interest for the clinical researchers
involved, and thus no further discussion is required, this would be an oversim-
plification of the problem. The Institute of Medicine defines a conflict of inter-
est as “a set of circumstances that creates a risk that professional judgment or
actions regarding a primary interest will be unduly influenced by a secondary
interest” (IOM, 2009). Because the researchers participating in the study
Dr. Cézanne and the Art of Re(peat) Research 91
would receive a “finder’s fee” for enrolling patients in the study, a conflict of
interest might arise if they have patients whose best interests would not be
served by participation in the study. But there still seem to be problems with
the study even if the researchers do not accept a finder’s fee, and these prob-
lems stem from the fact that factors other than personal income are at stake.
If we broaden the discussion from one of conflicts of interest to one of compet-
ing obligations, it becomes easier to see these factors and the problematic role
they play and, ultimately, to come to a position on the proposed research.
As clinicians, with primary obligations to their patients, Dr. Cézanne and
his colleagues are obligated to act in accordance with their patients’ wishes
and in their patients’ best interests (according to their patients’ conception of
their best interest). As scientists, they are obligated to increase medical
knowledge for the benefit of others in the future. As employees (or as individu-
als with university appointments and hospital privileges), they are required to
participate in the training of students, to contribute to the generation of
knowledge, and, increasingly, to contribute to their institutions’ financial
well-being. We suggest that a closer look at the challenge of managing these
competing obligations provides clues as to how to resolve the dispute between
Dr. Cézanne and his colleagues.
Participation in a clinical trial may be beneficial to a patient, in that it
may give her the opportunity to try a new and promising treatment well
before the therapy is available in regular clinical care. At the same time, how-
ever, by enrolling in the trial, the patient also runs the risk that she will not
benefit and she also gives up the relative certainty of the benefits of regular
clinical care. At the very least, this creates an obligation for the clinician-
researcher to fully explain the potential benefits and harms of participation in
the trial and the alternative of receiving standard therapy.
It is important to note here, however, that society has placed restrictions
on how much risk a patient can be asked or allowed to assume (or, conversely,
how much benefit she can ethically be asked or allowed to forego) through par-
ticipation in a clinical trial. Specifically, a state of clinical equipoise must
obtain in order for a trial to be ethically justifiable. Benjamin Freedman
(1987) defined clinical equipoise as a state of honest, professional disagree-
ment among the relevant medical community as to the best treatment. It
must be unclear to the experts whether the experimental intervention will be
as or more safe and effective than the currently accepted standard of care (or,
where there is none or where the standard of care has not been shown to be
better than placebo, as or more effective than placebo).
These rules do place limits on the physicians’ obligations to act in accor-
dance with the wishes of their patients but they do so, in part, to correct for a
power imbalance between participants on the one hand and research sponsors
on the other. Potential participants have an interest in accessing a drug that
they believe may benefit them. Research sponsors have an interest in conducting
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research in the cheapest way possible with the greatest chance of being able to
claim superiority for their drug (e.g., placebo vs. active controls). Without the
rules, the research sponsors could force participants to accept inferior control
arms (i.e., placebo over standard of care) in order to gain even the possibility
of access to the drug.
Given the rules, the most the physician could have an obligation to do
(under obligations to patients), is to offer them the opportunity to participate
in a trial where clinical equipoise exists and where standard therapy is the
control. Neither of these conditions applies in this scenario. Therefore, the
physicians do not have any obligation under obligations to patients to offer
this trial to their patients.
Clinical equipoise is also an important principle in the analysis of the
clinician-researchers’ obligations to advance medical knowledge for the bene-
fit of others in the future. Resources spent on this trial will not be available to
spend on other trials. These resources include clinic facilities time as well as
scarce human resources. If clinical equipoise does not exist, then surely better
uses for these resources could be found. The study in Dr. Cézanne’s scenario
will not enable the players to advance medical knowledge and so, at best, will
not contribute to them meeting their obligations; it will, at worst, interfere
with their ability to meet their obligations (by distracting them from studies
that could actually advance medical knowledge).
In sum, so far, we have seen that for Dr. Cézanne and his colleagues, pro-
ceeding with this clinical trial will not help them to attend to their obligations
as clinicians (who must act according to their patients’ wishes and in their
patients’ best interests as seen by the patients) and as scientists (who must
conduct research that is both ethical and of scientific value) within the limits
society has placed on those obligations. A “re(peat)search” study, such as the
one described here, being of questionable scientific value and requiring
patients to accept worse care than they would receive in regular clinical prac-
tice in order to access the experimental intervention, fails with respect to both
of these sets of obligations.
However, Dr. Cézanne and his colleagues have another set of obligations
that may seem to push them in the direction of approving the study. These are
their obligations to the institution where they work. As employees (or individ-
uals with appointments and privileges), they are required to participate in the
training of students, contribute to the generation of knowledge, and, increas-
ingly, to contribute to their institutions’ financial well-being.
If Dr. Cézanne and his colleagues participate in the study, their institu-
tion will receive funding that can be used to support trainees and to cover
infrastructure costs. In fact, it is increasingly common that research institutions
receive a significant portion of their operating funds from industry-sponsored
research. This research may be contracted by the industry partner, or may be
a joint venture undertaken with the hope of commercializable results. The
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increase in such research is due both to the hope of profitable research and to
the fact that government funding of universities and other research institutes
(both directly and through granting programs) has not kept pace with the
increasing costs of running the institution or with the costs of research itself.
These changes in the way in which universities are funded have resulted in
changes to obligations that researchers have toward them. Increasingly,
researchers’ time is spent trying to attract funding for their own research, a
portion of which is kept by the university to cover its costs. This study will, of
course, help with all of this and so contribute to Dr. Cézanne and his
colleagues meeting their obligations with respect to the financial well-being of
their institution.
However, the study will undermine their ability to meet their other obliga-
tions which arise as a result of their relationship with the institution: teach-
ing and creating new knowledge. At first blush, it might appear otherwise.
Students who work on the study will certainly learn about research and some
knowledge will be produced through the research. But will the lessons the stu-
dents learn be good ones, and will the knowledge gained be new and useful for
science or medicine?
We would argue that the duty of the university is actually broader than
the mere teaching and the mere acquisition of knowledge. We would argue
that universities have a duty to educate students and to develop knowledge
in ways that can be used to benefit society. Universities should not simply
become a source of researchers for hire for corporations. Universities should
not simply become factories for knowledge that serves the marketing pur-
poses of industry. Requiring that studies undertaken by academic institu-
tions have social or scientific value prevents these consequences from being
realized.
The study debated by Dr. Cézanne and his colleagues fails the test of
social or scientific value both in terms of teaching and knowledge generation:
the students will learn to devote their time and intellectual energy to the
highest bidder rather than the health of their patients and future patients;
and a number of other effective treatments are already available, and the
study’s purpose is not to answer a scientific question (it is already known that
the drug is effective). Therefore, while the obligation to generate resources can
be met through this study, the clinician-researchers’ obligations to their insti-
tution in respect of teaching and knowledge generation cannot.
In sum, agreeing to run this clinical trial will not serve the clinician-
researchers’ obligations as clinicians or as researchers. Nor will it serve two of
their three kinds of obligations as employees (or as individuals with appoint-
ments and privileges)-–it will enable them to generate funds but not to meet
the teaching and knowledge generation mandates of a university. Thus, the
competition is relatively easy to resolve-–money against all else-–and they
should not agree to run the study.
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